Individual Patient Expanded Access-Glembatumumab Vedotin

Summary

Celldex endeavors to make investigational products available to patients with life-threatening diseases who have exhausted other treatment options and where there is a reasonable expectation of benefit over risk. Requests for expanded access to glembatumumab vedotin in patients with gpNMB expressing triple negative breast cancer will be considered.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications